Abstract
Supplementary Figure S8. Co-Alteration Landscape Of ERBB2 Mutated Tumors In Select Cancers The prevalence of oncogenic co-alterations was compared for ERBB2 MUT (excluding samples w/ ERBB2 co-amplification) versus ERBB2 WT (non-mutated and non-amplified) a) NSCLC, b) Breast, c) CRC, d) Bladder, e) GEC, f) MSS CRC, and g) MSS GEC tumor samples profiled using tissue CGP. Only genes altered in at least 50 tumors and targeted across all tissue CGP assay versions were included. For each gene, mutations (SNVs, Indels), rearrangements, and copy number changes of known or likely functional significance detected using our assay were included. Genes highlighted in the National Comprehensive Cancer Network (NCCN) Guidelines as molecular drivers as well as genes altered at a high prevalence (≥10%) in either cohort are labeled for each volcano plot if a statistically significant difference was observed (p < 0.05, threshold indicated by dashed line). ERBB3, if statistically significant, is also labeled. Fisher’s Exact Test was performed to assess patterns of co-occurrence/mutual exclusivity between ERBB2 and other genes. P values were corrected using the Benjamini-Hochberg FDR method. MSS, Microsatellite Stable.